Found: 8
Select item for more details and to access through your institution.
Mayo‐PACC: Optimizing a parsimonious Preclinical Alzheimer's disease cognitive composite comprised of public‐domain measures.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.064547
- By:
- Publication type:
- Article
Mayo‐PACC: A parsimonious preclinical Alzheimer's disease cognitive composite comprised of public‐domain measures to facilitate clinical translation.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 6, p. 2575, doi. 10.1002/alz.12895
- By:
- Publication type:
- Article
Convergent and criterion validity of a computer adaptive self‐administered word list memory test and the Mayo Test Drive composite: correlations with traditional measures and group difference by PET imaging biomarker status in persons without dementia
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 7, p. 1, doi. 10.1002/alz.063723
- By:
- Publication type:
- Article
Diagnostic accuracy of the Stricker Learning Span and Mayo Test Drive Composite for amnestic Mild Cognitive Impairment.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 7, p. 1, doi. 10.1002/alz.063190
- By:
- Publication type:
- Article
Mayo normative studies: A conditional normative model for longitudinal change on the Auditory Verbal Learning Test and preliminary validation in preclinical Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2022, v. 14, n. 1, p. 1, doi. 10.1002/dad2.12325
- By:
- Publication type:
- Article
A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).
- Published in:
- 2019
- By:
- Publication type:
- Correction Notice
Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).
- Published in:
- Journal of Neuro-Oncology, 2019, v. 143, n. 3, p. 573, doi. 10.1007/s11060-019-03194-z
- By:
- Publication type:
- Article